In Brief
This article was originally published in The Tan Sheet
Executive Summary
FDA reverses on OTC PPI fracture risk
You may also be interested in...
Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels
Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.
In Brief
Prestige Brands gains from acquisitions
In Brief
Colgate Buys Sanex Deodorants